



Welcome to

InDex Pharmaceuticals Capital Markets Day

April 25, 2018

Agenda of the Day

- 9:15 Introduction Peter Zerhouni, CEO InDex Pharmaceuticals
- 9:30 Ulcerative colitis a debilitating disease with high unmet medical need Professor Walter Reinisch, Medical University of Vienna
- 10:00 Cobitolimod a promising first in class drug candidate for the treatment of ulcerative colitis - Professor Raja Atreya, University of Erlangen-Nürnberg, Principle Investigator in the CONDUCT study
- 10:30 Panel discussion
- 10:40 Coffee break
- 10:50 The phase IIb study CONDUCT Dr Thomas Knittel, Chief Medical Officer InDex Pharmaceuticals
- 11:05 Implementation of the CONDUCT study Pernilla Sandwall, Chief Operating Officer InDex Pharmaceuticals
- 11:20 Cobitolimod's market potential Peter Zerhouni, CEO InDex Pharmaceuticals
- 11:45 Q&A
- 12:00 Lunch and mingle





Introduction

Peter Zerhouni CEO InDex Pharmaceuticals

Forward Looking Statement

This presentation contains certain forward-looking statements reflecting the Company's current view of future events and financial and operational performance. Such forward-looking statements are associated with both known and unknown risks and circumstances outside the Company's control. All statements in this presentation other than statements of historical or current facts or circumstances are forward-looking statements. Forward-looking statements are made in several sections of the presentation and can be identified by the use of terms or expressions such as "may", "could", "should", "anticipated", "estimated", "expected", "likely", "forecasted", "plans to", "aims to", or conjugations of such terms or similar terms. The forward-looking statements only apply as of the date of this presentation. The Company has no intent or obligation to publish updated forward-looking statements or any other information contained in this presentation based on new information, future events etc. other than required by applicable law, regulation or regulatory framework.



InDex Pharmaceuticals in Brief

- Based in Stockholm, Sweden with origins from Karolinska Institutet
 - Focus on immunological diseases with high unmet medical need
- Cobitolimod for ulcerative colitis in late stage clinical development
 - Phase IIb dose optimisation study now recruiting (CONDUCT)
 - Strategy to partner cobitolimod prior to phase III
- Broad portfolio of pre-clinical stage assets from DIMS platform
 - DNA based ImmunoModulatory Sequences
 - Potential in inflammatory diseases
- IPO in 2016 of SEK 250 million (EUR 25 million) to finance CONDUCT study
- Listed on the Nasdaq First North Stockholm (ticker INDEX)
 - SEB Venture Capital, 23%
 - Industrifonden, 21%
 - NeoMed Management/N5, 11%



Cobitolimod



Board of Directors with Proven Track Records

Dr. Wenche Rolfsen

Chairman of the Board since 2011 Chairman of BioArctic, board member of Swedish Match and Recipharm Previous leading positions at Pharmacia and Quintiles

Dr. Uli Hacksell *Director since 2015* Board member of Uppsala University Previous CEO of Cerecor, ACADIA and executive positions at Astra

Stig Løkke Pedersen Director since 2012 Chairman of Nuevolution and Transmedia Previous Chief Commercial Officer at Lundbeck



Dr. Lennart Hansson *Director since 2011* Senior Advisor to Industrifonden Previous CEO Arexis, senior positions at Astra

Andreas Pennervall Director since 2016 Employed by SEB Venture Capital



Management Team with Industry Experience

Peter Zerhouni, CEO

Previous CEO and Head of Business Development at Diamyd Medical

Pernilla Sandwall, COO

Previous leading positions within Clinical Operations at Merck&Co/MSD



Dr. Thomas Knittel, CMO Gastroenterologist, previous Director Medical Marketing at Novo Nordisk

Johan Giléus, CFO Previous partner at Deloitte



Flexible and Cost Efficient Organisation

- Core team of 17 employees and fixed consultants
- Outsource development work to CROs/CMOs
- Scientific Advisory Board
- Expert panel of Key Opinion Leaders





Portfolio of More than 150 Different DIMS

DIMS	IFN-α	IFN-β	IFN-γ	IL-6	IL-10	TNF	Mer
DIMS-9002	-	-	-	+	++	-	24
DIMS-9012	-	-	-	++	++++	-	27
DIMS-9020	++++	+++	-	-	-	-	23
DIMS-9024	-	-	-	++	+++	-	23
DIMS-9025	++	-	-	+	++	-	23
DIMS-9049	+++++	+++++	-	+++	+++	-	17
DIMS-9050	+++++	+++	-	+	++	-	17
DIMS-9052	+++++	+++++	-	-	-	-	14
DIMS-9054	+++++	++++	-	++	+	-	15
DIMS-9055	+++++	++++	+	+++	++	-	20
DIMS-9059	+++++	++++	(+)	+++++	+++	-	12
DIMS-9061	+++	-	-	+	-	-	18
DIMS-9067	+++++	+++++	++	++++	++++	-	21
DIMS-9069	-	-	-	+++	++++	-	26
DIMS-9074	-	-	-	+++	+++++	-	19
DIMS-9075	-	-	-	-	++	-	20
DIMS-9078	++	-	-	+	++	-	14
DIMS-9097	-	-	-	+	++	-	18

+++++ +++	high mid
+	low
(+)	very low
-	none

InDex has designed a broad portfolio of new TLR9 agonists with different characteristics with potential in inflammatory disease. Concept will be validated by cobitolimod



InDex Aims to Broaden the Development Pipeline


- Pre-clinical development of additional DIMS substances, in order to diversify the clinical pipeline
- Inflammatory diseases outside of ulcerative colitis and inflammatory bowel disease
- Leverage historical investments in generating DIMS portfolio
- Leverage pharmaceutical development experience, expertise and knowledge gained from the development of cobitolimod
- VINNOVA grant of SEK 1.8 million for the development, until end of 2018



Financial Overview 2017

- Revenues amounted to SEK 0.1 (0.4) million
- Operating result amounted to SEK –73.3 (–39.5) million
- Cash flow from operating activities amounted to SEK –68.2 (–31.9) million
- Cash and cash equivalents at the end of the period amounted to SEK 125.1 (193.2) million

All comparative amounts in brackets refer to the outcome of InDex's overall activities during the corresponding period 2016





InDex Strengths

BLOCKBUSTER POTENTIAL

- Ulcerative Colitis (UC) is a debilitating disease with high unmet medical need
- Annual sales of biologics in UC amounts to >USD 5 billion
- Cobitolimod has high market potential as a safer and more efficacious alternative to biologics with a novel mechanism of action

LATE STAGE CLINICAL DEVELOPMENT


- Extensive clinical experience with excellent safety profile
- Main results from phase IIb dose optimisation study expected in Q4 2018
- Potential to provide substantially higher efficacy than current industry pipeline
- Attractive asset for potential partners
- Will validate broad portfolio of other DIMS assets with potential in inflammation

EXPERIENCED BOARD & MANAGEMENT

 Board and management with extensive experience from the pharmaceutical industry and listed companies



Ulcerative colitis - A Debilitating Disease with High Unmet Medical Need



Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien, MUW




Crohn's disease and ulcerative colitis are two different diseases

Crohn's disease


- Patchy inflammation
- Entire gastrointestinal (GI)
- All layers of GI wall (fistulas and strictures)
- T_(H)1 response
- Smoking: risk factor
- Risk of cancer
- Extra-intestinal manifestations

Ulcerative colitis


- Continuous inflammation
- Colon and rectum only
- Mucosal and sub-mucosal layers
- T_(H)2 response
- Smoking: protective (nicotine)
- Risk of cancer
- Extra-intestinal manifestations



Proinflammatory immune cells and their crosstalk in patients with IBD




Imbalance of Intestinal Flora in IBD



Gevers et al. Cell Host & Microbe 2014

UC: disease extension




- Tenesmus, urgency
- Faecal incontinence
- Passage of mucus and fresh blood

Left-sided colitis



- Bloody diarrhoea
- Sometimes proximal constipation

Pancolitis



- Bloody Diarrhoea
- Weight loss
- Fever
- Clinically significant blood loss
- Abdominal pain

Dignass A, et al. J Crohns Colitis 2012;6:965-990;

http://www.hopkins-gi.org/GDL_disease.aspx?GDL_Disease_ID=2A4995B2-DFA5-4954-B770-F1F5BAFED033&GDL_DC_ID=D03119D7-57A3-4890-A717-CF1E7426C8BA

Mayo Classification of Ulcerative Colitis by Endoscopic Findings



pattern

pattern, friability,

erosions

ulceration

6

UC as a disabling disease: loss of function

IBD Disability Index

ANSWERS: 1 = None, 2 = Mild; 3 = Moderate; 4 = Severe; 5 = Extreme or cannot do	1	2	3	4	5
Regulating defecation					
8. Overall in the last week, how much difficulty did you have coordinating and managing defecation including choosing and getting to an appropriate place for defecation and cleaning oneself after defecation? (d5301)					

Incontinence Tenesmus Urgency



Peyrin-Biroulet L, et al. Gut 2012;61:241–7

The Clinical Heterogeneity of Ulcerative Colitis

Disease pattern:

- continuous discontinuous
- rectum sparing
- cecal patch
- backwash ileitis
- duodenal involvement
- primary sclerosing cholangitis etc.

Disease extent


Disease severity

Age at onset


Disease course

Serology

Response to treatment





Natural Course of Ulcerative Colitis




Curve 1: Remission or mild severity of intestinal symptoms after initial high activity

6% (n=22)






Curve 2: Increase in the severity of intestinal symptoms after initial low activity



Solberg IC, et al. Scan J Gastroenterol 2009;44(4):431–440

Ulcerative Colitis: cumulative rate of colectomy



Solberg IC, et al. Scand J Gastroenterol 2009;44:431-40

Gower-Rousseau C, et al. Am J Gastroenterol 2009;104:2080-8

Colectomy in UC: potential complications


- Mortality (<0.5%)¹
- Small-bowel obstruction²
- 5–10 stools / 24 hr³
- Faecal incontinence³

- 1. Ferrante M, et al. Inflamm Bowel Dis 2008;14:20-8
- 2. Ochsenkühn T, et al. Gut 2011;60:1294–9
- 3. Pemberton JH, et al. Ann Surg 1987;206:504–13
- 4. Krausz MM, et al. Isr Med Assoc J 2005;7:23-7
- 5. Ørding Olsen K, et al. Gastroenterology 2002;122:15–9
- 6. Johnson P, et al. Dis Colon Rectum 2004;47:1119–26
- 7. Gorgun E, et al. Surgery 2004;136:795–803

- Pouchitis (46%)^{1,2}
- Pouch fistulae²
- Impotence (1.2%)⁴
- Reduced female fertility (54– 98%)^{2,5–7}

Estimates of mortality in IBD

Risk of dying according to age at, and time since, IBD diagnosis (Denmark 1982–2010) 36,080 UC and 15,361 CD vs 2,858,096 matched controls



- Mortality increased in the first year after diagnosis
- Intermediate and long-term mortality increased by 10% in UC and 50% in CD
- Mortality from UC decreased from 1982– 2010, because of reduced mortalities from GI disorders and colorectal cancer
- Mortality from CD did not change

Control persons

Ulcerative colitis

Crohn's disease

Jess T, et al. Clin Gastroenterol Hepatol 2013;11:43-8

Treatment Targets in Ulcerative Colitis

Absence of ulceration


AND

Resolution of Patient Reported Outcomes (PROs)

Clinical Endpoints: Lost in Translation



Current Treatment Algorithm of Ulcerative Colitis



Significant Unmet Need Exists for Safe, Efficacious and Convenient Alternative to Biologics and Other Systemic Therapies, Particularly in Moderate-Severe Patients.

Long Term Remission Rates Suboptimal in Ulcerative Colitis

- One year clinical remission: 16% to 35% in treat-through studies (ADA, IFX) and 23% to 42% in re-randomization studies (GLM, VDZ)
- Steroid free and long-term remission rates are lower
- The rates of endoscopic healing are lower
- Lower remission rates in patients previously exposed to biologics
- New endpoints, e.g. histologic remission or biomarker remission are even more difficult to achieve
- Safety issues with approved biologics and immunomodulators

How to Optimize Treatment Outcomes

- Clinically-driven dose optimization
- Tight monitoring of patient reported outcomes
- Tight monitoring of inflammatory biomarkers (CRP, fCP)
- Therapeutic drug monitoring (TDM)
- Combination therapy
- Precision medicine
- Endpoint validation


Modes of Action in UC

Anti-Inflammation

- JAK inhibitors
- PDE4 inhibitors
- TLR9 agonist

Barrier enhancement

- Microbiota Modulation
- Phosphatidylcholine




Cytokines

- Anti-TNF α
- Anti-IL-12/23

Cell Migration

- Anti-integrins:
 - Anti-α4β7
 - Anti-β7
 - Anti-MadCAM
- S1P1R modulation


Tofacitinib: Remission – primary endpoint




* p=0,007 vs. Placebo, ** p<0,001 vs. Placebo

Sandborn WJ et al. N Engl J Med 2017; 376(18):1723-1736.

Apremilast: remission – primary endpoint



Potential Future Treatment Algorithm of Ulcerative Colitis



Significant Unmet Need Exists for Safe, Efficacious and Convenient Alternative to Biologics and Other Systemic Therapies, Particularly in Moderate-Severe Patients.



- There is an unmet need in the management of UC on various dimensions:
 - Understanding the biology and heterogeneity of the disease
 - Endpoint are lacking validity, granularity and relevance
 - Treatment optimization strategies in UC are missing
 - There is a dire need of new mode of actions





MEDIZINISCHE FAKULTÄT



Cobitolimod

A promising first in class drug candidate for the treatment of ulcerative colitis

Professor Raja Atreya University of Erlangen-Nürnberg

Cobitolimod is a First in Class TLR9 Agonist

Cobitolimod is an oligonucleotide which activates Toll Like Receptor 9 (TLR9) by mimicking microbial DNA Cobitolimod

Modulation of the mucosal immune system

Local anti-inflammatory effect Healing of the colonic mucosa



Toll-like Receptor 9 (TLR9)

- TLRs are key pattern recognition receptors of the innate immune system
- TLR9 is expressed in intestinal immune cells and on the surface of epithelial cells
- TLR9 recognizes unmethylated CpG sequences of bacterial and viral DNA
- Cobitolimod contains a CpG motif that can mimic the natural ligand of TLR9 and induce immunomodulatory effects
- Binding of cobitolimod to TLR9 aims to restore the innate immune function and balance the immune cells




Cobitolimod - Clinical Development Overview

STUDY TYPE	NO. OF PATIENTS	YEAR
Pilot (1x30mg)	11	2001
Dose finding study, CSUC-01/02 (1x0.3mg-100mg)	151	2005
Phase II CSUC-01/06 (1x30mg)	34	2009
Compassionate Use (1-3x30mg)	14	2011
COLLECT (2x30 mg)	130	2014



COLLECT Study Design



COLLECT was conducted with the global company Covance as the CRO

Demographics of Patients at Baseline

ТҮРЕ	PLACEBO (n=43)	COBITOLIMOD (n=81)	OVERALL (n=124)
Age (yr)	43.1	41.1	41.8
Gender f/m (%)	26/74	41/59	36/64
Smoker (%)	7.0	6.2	6.5
UC duration (yr)	9.1	9.2	9.2
CAI score, mean	11	11	11
Endoscopic Mayo score, mean	2.6	2.6	2.6
Histologic Geboes score, mean	3.6	3.6	3.6




Anti-TNF-Antibody Exposure

	PLACEBO (n=43)	COBITOLIMOD (n=81)
Anti-TNF experienced	39.5% (n=17)	38.5% (n=31)
Anti-TNF naive	60.5% (n=26)	61.5% (n=50)



Primary Endpoint with an Unexpected High Placebo Rate

Induction of Clinical remission at week 12 according to Rachmilewitz/CAI score ≤4





UC Index Scores: Relevant Endpoints are Underweighted in CAI

- Stool frequency
- Rectal bleeding
- Endoscopy

are the **most relevant** subscores and are **under-represented** in the CAI score.

 Regulators require Mayo Activity Index without the subjective Physician Assessment

		IFX ADA
	Cobit	VDZ
UC Scores	Clinical Activity Index (CAI)	Mayo Activity Index (DAI)
Stool Frequency	0-3	0-3
Rectal Bleeding	0-4	0-3
Endoscopy		0-3
Physician Assessment	0-3	0-3
Abdominal Cramps	0-3	
Extraintestinal manifestations (iritis, eritema nodosum, arthritis)	0-9	
Temperature	0-3	
Lab. findings (ESR, Hb)	0-4	
Total max score	29	12




High Placebo Rate in the Primary Endpoint of COLLECT Driven by "Stringency" and "Time"

- Missed primary endpoint at week 12 due to unexpected high placebo rate
 - Clinical remission defined as Rachmilewitz/CAI score ≤4
- The high placebo remission rate is understood and driven by:
 - No hard definition of primary endpoint
 CAI ≤4 too noisy endpoint, no requirements on the subscores
 - 2. No robust scoring system for UC disease activity CAI score too UC unspecific, known to induce high placebo rates, not used anymore
 - **3.** Time point of primary endpoint too late (week 12) Spontaneous remission due to nature of the disease & concomitant medication All patients on concomitant glucocorticosteroids




Cobitolimod Induces Significant Improvement in Key Symptoms at Week 4



Induction of patient reported remission at week 4 defined as no blood in stool & stools per week <35 Induction of mucosal healing at week 4 defined as endoscopic Mayo score of 0 or 1




Cobitolimod Improves Histopathological Disease Activity Score at Week 4



Histological evaluation according to the method described by Geboes (score 0: normal mucosa to score 5: erosions/ulcerations; biopsies taken from most inflamed areas)




70% of Remitters at W4 Maintain Remission at W12



Patient reported remission and mucosal healing: *blood in stool = 0, weekly stool <35 with mucosal appearance of 0 or 1*




Efficacy in both anti-TNF Naïve and Exposed Patients



Patient reported remission at week 4 defined as no blood in stool, stools per week <35



Cobitolimod Reduces the Rate of Colectomy



Parameter	S.o.C + Placebo (N=31)	S.o.C + Cobitolimod (N=68)	Δ(%)
At 5 months	3 (9.7)	1 (1.5)	8.2
At 12 months	3 (9.7)	2 (2.9)	6.8



Cobitolimod has a Good Safety Profile

TREATMENT-EMERGENT ADVERSE EVENTS (SAFETY ANALYSIS SET)	S.O.C + PLACEBO (n=43) n (%)	S.O.C. + COBITOLIMOD (n=87) n (%)	OVERALL (N=130) n (%)
Patients with AEs	25 (58.1)	52 (59.8)	77 (59.2)
Patients with Gastrointestinal AEs	6 (14.0)	16 (18.4)	22 (16.9)
Patients with Serious AEs	8 (18.6)	10 (11.5)	18 (13.8)
Deaths	0	0	0
Patients with Treatment Related AEs	4 (9.3)	10 (11.5)	14 (10.8)
Patients with Treatment Related SAEs	1 (2.3)	3 (3.4)	4 (3.1)
Patients with AEs Leading to Discontinuation	1 (2.3)	2 (2.3)	3 (2.3)



COLLECT Study Successfully Published in JCC

Journal of Crohn's and Colitis, 2016, 1294–1302 doi:10.1093/ecco-jcc/]jw103 Advance Access publication May 20, 2016 Original Article

OXFORD

Original Article

Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis

Raja Atreya^a, Stuart Bloom^b, Franco Scaldaferri^c, Viviana Gerardi^c, Charlotte Admyre^d, Åsa Karlsson^d, Thomas Knittel^d, Jan Kowalski^o, Milan Lukas^f, Robert Löfberg^{s,h}, Stephane Nanceyⁱ, Robert Petryka^j, Grazyna Rydzewska^{kJ}, Robert Schnabel^m, Ursula Seidlerⁿ, Markus F. Neurath^a, Christopher Hawkey^o

*Medical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany *Gastroenterology, University College London Hospital, London, UK 'Internal Medicine Department/Gastroenterology Division, Catholic University of Rome, Rome, Italy 'InDex Pharmaceuticals, Tomtebodavägen 23A, 171 77 Stockholm, Sweden 'XK Biostatistics AB, Stockholm, Sweden 'Clinical Centre Isacre Lighthouse, IBD Clinical and Research Centre, Prague, Czech Republic *Stockholm Gastro Center, Sophiahemmet, Stockholm, Sweden *Department of Medicine, Karolinska Institutet, Solna, Sweden 'Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France NZOZ Vivamed, Warsaw, Poland 'Central Clinical Hospital Ministry of Interior in Warsaw, Warsaw, Poland 'Jan Kochanowski University, Kielce, Poland *Pannonia Maganorvosi Centrum, Budapest, Hungary *Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany *Department of Gastroenterology, Nottingham Digestive Diseases Centre, Nottingham University Hospitals, Nottingham, UK

Corresponding author: Christopher Hawkey, Professor of Gastroenterology, Nottingham Digestive Diseases Centre, Noitingham University Hospitals, Derby Road, Nottingham NG7 2UH, UK. Tel: 44-115-823-1033; Fax: 44-115-823-1409; Email: cj.hawkey@nottingham.ac.uk

Conference Presentations: Part of this work has been presented at the European Crohn's and Colitis Organisation Conference 2015 [Barcelona], Digestive Disease Week 2015 [Washington] and United European Gastroenterology Week 2015 [Barcelona].

The clinical trial registration number is NCT01493960 and EudraCT number 2011-003130-14.

Abstract

Background and Aims: Toll-like receptors [TLRs] are potential drug targets for immunomodulation. We determined the safety and efficacy of the TLR-9 agonist DNA-based immunomodulatory sequence 0150 [DIMS0150] in ulcerative colitis [UC] patients refractory to standard therapy. Methods: In this randomized, double-blind, placebo-controlled trial, 131 patients with moderate-

to severe active UC were randomized to receive two single doses of the oligonucleotide DIMS0150 [30 mg] or placebo administered topically during lower GI endoscopy at baseline and Week 4. The primary endpoint was clinical remission, defined as Clinical Activity Index [CAI] ≤4, at Week 12. Secondary endpoints included mucosal healing and symptomatic remission of key patient-reported outcomes [absence of blood in stool and weekly stool frequency <35].

Results: There was no statistical significant difference between the groups in the induction of clinical remission at Week 12, with 44.4% in the DIMS0150 group vs. 46.5% in the placebo group. However, the proportion of patients who achieved symptomatic remission was 32.1% in the DIMS0150 group vs. 14.0% in the placebo group at Week 4 [p = 0.020], and 44.4% vs. 27.9% at Week 8 [p = 0.061]. More patients on DIMS0150 compared with those on placebo had

Journal of Crohns and Colitis, 2016 Nov;10(11):1294-1302



© European Crohn's and Colitis Organisation 2016.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ licenses/by/4.0%), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.


New Mechanism of Action Data for Cobitolimod Presented at the 2018 ECCO Congress

- The data were presented orally during the single track scientific program at ECCO
 - The largest IBD congress in the world with more than 6000 delegates
- The scientific abstract was selected amongst the top 10 out of 1,366 submitted abstracts
- Th17/Treg and Th2/Th1 immune imbalance plays a crucial role in the development of UC
- The data show that cobitolimod can balance the mucosal Th17/Treg cell response in UC






Cobitolimod Ameliorates Experimental Colitis by modulating the Th17/Treg imbalance






Cobitolimod Decreases IL17 & IL6 & Increases IL10 production in cultured mucosal cells of UC patients



Expression of different cytokines in LPMCs from UC patients stimulated with LPS in vitro with or without cobitolimod, $p \le 0.05$, $p \le 0.01$, $p \le 0.001$



Cobitolimod Increases IL10+ and FOXP3+ and Decreases IL17+ Intestinal Cells in UC Patients




*p<0.05



Cobitolimod Induces an Anti-Inflammatory Milieu that Balances the Immune System in UC

- Topical luminal administration of cobitolimod modulates the immune response in patients with active UC
- Cobitolimod application induces anti-inflammatory (IL10) and suppresses proinflammatory (IL17, IL6) cytokine production
- Cobitolimod modulates the Th17/Treg imbalance in mucosal inflammation



Cobitolimod - A Promising Novel Therapy in UC

- Cobitolimod is a potential new medication for moderate to severe ulcerative colitis
- Cobitolimod has achieved clinical proof of concept with a very favorable safety profile
- 4 completed clinical studies, 249 patients treated with cobitolimod
- Novel and unique mechanism of action in late stage clinical development for UC
- High efficacy with good safety profile
- Local treatment, provides rapid onset of action








The phase IIb study CONDUCT

Dr Thomas Knittel Chief Medical Officer InDex Pharmaceuticals


COLLECT STUDY Cobitolimod Induces Significant Improvement in Key Symptoms at Week 4



Induction of patient reported remission at week 4 defined as no blood in stool & stools per week <35 Induction of mucosal healing at week 4 defined as endoscopic Mayo score of 0 or 1




Meta Analysis of Three Independent Placebo-Controlled Clinical Studies Provide Proof of Concept



Clinical Remission defined as Mayo score (or converted CAI for COLLECT) ≤2 with no subscore exceeding 1




STUDY CSUC-01/02 Clinical Data Supports Improved Efficacy with Higher Doses



Clinical remission defined as Mayo score = 0 at week 4



Cobitolimod Induces Dose Dependent Release of IL-10 in Human Cells



IL-10 release from PBMCs stimulated with different concentrations of cobitolimod




Cobitolimod has Excellent Safety Profile

- 249 patients dosed in completed studies
 - Side-effect profile same as placebo in all studies
 - No drug related serious adverse events
- Extensive toxicology package performed in rodent and monkey
 - Rectal, i.v. bolus, and s.c. route of administration investigated up to 100 mg/kg
 - Maximum Tolerated Dose was not reached
 - Only mild inflammation at injection site (s.c. only) and marginal increase in spleen weight observed, effects reversible
 - Toxicology package supports dosing regimens in the CONDUCT phase IIb study



Potential to Further Increase the Efficacy of Cobitolimod

- Competitive efficacy in clinical trials with low and infrequent dosing of cobitolimod
- Excellent safety profile in clinical trials and toxicology studies
- Room for increasing dose and dosing frequency
- Clinical and preclinical data supporting dose dependent efficacy





The Phase IIb Dose Optimisation Study CONDUCT

Study title

A randomised dose optimisation study to evaluate the efficacy and safety of cobitolimod in moderate to severe active ulcerative colitis patients

Primary objective

To evaluate the efficacy of cobitolimod treatment at different dose levels and frequencies compared to placebo with regard to clinical remission 6 weeks after first treatment, in patients with moderate to severe active ulcerative colitis



COLLECT Inputs for the CONDUCT Study Design

- Primary endpoint based on the Mayo score
- Earlier evaluation of primary endpoint
- Central reading of endoscopy
- Increase cobitolimod dose and/or frequency
- Concomitant steroids allowed, but not mandatory
- Use enema for administration of cobitolimod
- Left sided disease (approx. 70% of population)



Primary Endpoint and Patient Population


Primary endpoint

Clinical Remission at week 6 defined by Modified Mayo sub scores:i) rectal bleeding of 0ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline), andiii) endoscopy score of 0 or 1 (excluding friability)

Summary of inclusion/exclusion criteria

- Adult patients with moderate to severe active left sided UC, defined by a Modified Mayo score (excluding friability at grade 1) of 6 to 12 with an endoscopic sub score ≥2
- Current oral 5-ASA/Sulphasalazine use or a history of oral 5-ASA/Sulphasalazine use
- Current Glucocorticosteroid (GCS) use or history of GCS dependency, refractory, or intolerance
- Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following agents:
 - Immunomodulators, e.g. cyclosporine, methotrexate, AZA/6-MP, tacrolimus
 - TNF-α inhibitors and/or anti-integrins
- Concomitant treatment with cyclosporine, methotrexate, tacrolimus, TNF-α inhibitors, anti-integrins or similar immunomodulators not allowed

CONDUCT Study Design





Ubitolimod as Novel DNA-based Ulcerative Colitis Treatment





Implementation of the CONDUCT study

Pernilla Sandwall Chief Operating Officer InDex Pharmaceuticals

CONDUCT Study

- 215 patients will be included
- 90 clinics selected in 12 European countries: Czech Republic, France, Germany, Hungary, Italy, Poland, Romania, Russia, Serbia, Spain, Sweden and Ukraine





PAREXEL as the CRO (Contract Research Organisation)

- PAREXEL ranked amongst the top five highest-rated CROs globally (CenterWatch survey, April 2017)
- 18 900 employees across 51 countries
- Experience from over 30 studies in UC and Crohn's disease
 - Leaders in central reading of endoscopy images
- Subsidiaries in all CONDUCT countries providing local knowledge and language expertise
- Signed full contract January 2017



PAREXEL's CRAs - Key Players

Clinical Research Associates (CRAs) main role is to monitor clinical trials:

- Ensures compliance with the clinical study protocol
- Makes on-site visits to verify data and boost patient recruitment
- Assure that adverse events are correctly documented and reported
- Communicates frequently with personnel at the clinic
- Assure the protection of the rights, safety and well being of study patients





InDex is a Very Active Sponsor

- Visit the majority of the sites
- Investigator's meetings
- CRA meetings
- Close collaboration with PAREXEL at all levels
- Professors Atreya and Reinisch actively involved



CONDUCT Branding and Recruitment Material

- Material for patient recruitment
- Information about the study to clinicians and patients
- Internet/social media recruitment

conduct

CObitolimod as **N**ovel **D**NA-based Ulcerative Colitis Treatment

THANK YOU FOR YOUR CONTINUED PARTICIPATION IN THE CONDUCT STUDY

We approvide

your commitment

to helping us and

potentiai tuturo ments for

ulconative colda

We look forward

to seeing you

noon.

people with




History or presence of any clinically significant History or presence of any circularly significant disorder that, in the opinion of the investigator, could impact on patient's possibility to adhere to the protocol and protocol procedures or would confound the study result or compromis patient safety Concomitant treatment with curlose

- sthotrexate, tacrolimus TNF-α inhibitor ti-integrins or similar immunosuppress and immunomodulators at enrolment. Any prior treatment with such drugs must have en discontinued at least 8 weeks prior to visit 1a or have non-measurable serum concentration levela
- Treatment with rectal GCS, 5-ASA/SP or tacrolimus within 2 weeks before visit 1b Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDa) within two weeks prior to visit 1s (one short treatment regime for antibiotics and occasional use of NIANDO exclamations and occasional use of SAIDS are allowed)
- Serious active infection Gastrointestinal infections including positive Clostridium difficile stool assay 1. Currently receiving parenteral nutrition or
- blood transfusions Females who are lactating or have a positive serum pregnancy test during the screening
- 13. Women of childbearing potential not using reliable contraceptive methods (reliable methods are barrier protection, hormonal contraception, a-uterine device or abstinence) throughout duration of the study
- 4. Concurrent participation in another clinical stu Concurrent participation in another cinical six with investigational therapy or previous use of neestigational therapy within 5 half-lives and within at least 30 days after last treatment of the experimental product prior to enrolment 15. Previous exposure to cobitolimod



Inclusion/exclusion

criteria



If you would like to learn more about the CONDUCT Study, contact: DO YOU HAVE

conduct



C L

DO YOU HAVE

ULCERATIVE

COLITIS?

conduct



CONDUCT from a Patient Perspective

- 1. Informed consent (IC) The patient receives detailed information, and signs the IC form for participation
- 2. Screening Beview of criteria for study pa

Review of criteria for study participation


3. Randomisation

The patient is randomly assigned to either treatment with cobitolimod or placebo; no one knows which treatment is given

4. E-diary

The patient reports the symptoms daily


- 5. Visits to the clinic week 1-3 Additional study treatments, and study procedures
- 6. Primary efficacy at week 6 All data for the primary endpoint is collected
- 7. Follow-up visit at week 10 Last visit for procedures and data collection



Pharmaceutical


Status CONDUCT

- First patient enrolled in June, 2017
- The study is approved in 11 countries
- 78 clinics have been initiated
- Patient recruitment is developing as expected
- No safety concerns
- Objective to report top line results in Q4 2018





Recruitment in Previous Study COLLECT







copitolimod as Novel DNA-based

Ulcerative Colitis Treatment








Cobitolimod's market potential

Peter Zerhouni CEO InDex Pharmaceuticals





Clear Need for Safer and More Efficacious Drugs in Moderate to Severe UC

- Current biologics provide limited efficacy and have problems with tolerance and severe side effects
 - Anti-TNF-alpha (infliximab, adalimumab, golimumab) and anti-integrin antibodies (vedolizumab)
 - Deltas of 9-12% in phase III (remission rates for active drug versus placebo)
- >\$5 Bn per year of biologics sales globally in UC alone
 - >200,000 UC patients globally receive treatment with biologics
 - Average cost of \$20,000 per patient per year
- Assets in late stage pipeline have deltas of 10-20%
 - Several have increased risk of severe side effects



Late Stage Pipeline for Moderate to Severe UC

MECHANISM OF ACTION	SUBSTANCES IN PHASE IIB/III	COMPANY	EFFECT (DELTA) CLINICAL REMISSION	SAFETY
Anti-integrin	Etrolizumab	Roche	21%	
	SHP647	Shire	14%	
	AJM300	EA Pharma/Kissei	20%	
JAK inhibitor	Tofacitinib	Pfizer	10-13%	Infections, lymphoma, black box warning
	Upadacitinib	Abbvie	-	Not reported
	Filgotinib	Galapagos/Gilead	-	Not reported
	PF-06700841	Pfizer	-	Not reported
	PF-06651600	Pfizer	-	Not reported
S1P1R modulator	Ozanimod	Celgene	10%	Mild heart rate effect, elevated liver transaminase
	Estrasimod	Arena Pharmaceuticals	18.5%	
Anti-IL-12 & IL-23	Ustekinumab	Janssen	-	Infections, cancer, RPLS
	LY3074828	Lilly	-	Not reported
	Risankizumab	Abbvie	-	Not reported
PDE4 inhibitor	Apremilast	Celgene	17.8% (TNF naive)	Diarrhea, nausea
TLR9 agonist	Cobitolimod	In Dex Pharmaceuticals	15%	



Cobitolimod – InDex's Lead Drug Candidate

- Cobitolimod has novel and unique mechanism of action
- Cobitolimod has achieved clinical proof of concept with higher efficacy than biologics and a superior safety profile
- Local treatment, provides rapid onset of action
- Dose optimisation study aimed to provide substantially higher efficacy while maintaining the excellent safety profile

Cobitolimod has high market potential as a safer and more efficacious alternative to biologics



What is Expected from New Drugs for IBD? What can We Expect from Cobitolimod?

Different Mechanism of Action	V
Better rates of inducing clinical remission	V
Less "loss of response" in responders	V
 Efficacy in primary/secondary non-responders to anti-TNF 	V
 Evidence of efficacy and safety in combination therapy 	
Less immunogenicity	V
Less risk of infection	M
Less risk of general immunosuppression	M
 Agents with limited ability to cross the placental barrier 	



Source: D'Haens, UEGW 2014

Stable Drug Product with Competitive COGS

- Cobitolimod has a less complex manufacturing process than biologics, allowing for a competitive Cost Of Goods
- Synthetic oligonucleotide formulated in aqueous solution
- Intended storage condition is 5°C (current shelf life 36 months)
- Administered rectally as 50 ml solution to the site of inflammation
 - Physician administered in the CONDUCT study
 - Potential for a patient administered enema in phase III
- Oral formulation is being investigated as a follow-on for Life Cycle Management purposes



Primary Market Research Supports Product Profile

- InDex contracted with an expert consultancy in the field for a first wave primary market research study in the US and EU big 5
- Total of 148 patient responses received and 65 physician interviews
- Objectives
 - Gain insights on current UC patient pool and treatment choices
 - Test reaction to and gather feedback on draft cobitolimod Target Product Profile
 - Understand initial views on proposed formulation and mode of administration
- Overall response from physicians and patients to the product profile presented was positive
- Features such as *fast onset of action, efficacy, and tolerability* scored very highly



Cobitolimod has a Strong IP Position

KEY PATENT FAMILIES	GEOGRAPHIC AREA	STATUS	EXPIRE	PTE/SPC
Patent family 1	US/EP/JP	Granted	2026/2027	5 years
Patent family 2	US/EP/JP/AUS/CA	Granted	2026/2027	5 years
Patent family 3	US/EP/JP/CA	Granted US/JP Pending EP/CA	2032	5 years

- IP protection beyond 2030 in main markets
- InDex is pursuing additional IP opportunities
- In addition, cobitolimod will be subject to data protection as a new chemical entity
 - 10 years from market approval in Europe
 - 5 years from market approval in the US
 - 8 years from market approval in Japan



InDex Business Development

- Strategy to partner cobitolimod prior to phase III
 - Resources and expertise for phase III, registration and commercialisation
 - Upfront, milstones, royalty
- Planning for start of phase III in 2019
- Active business development effort
 - CEO, Senior BD Consultant, BD Manager, CMO
- Participate at main partnering conferences in US, Europe and Japan
- Presentations/posters at main GI/IBD congresses in US and Europe
- Clear demand from industry for promising assets within IBD
- Have established good contact with potential partners within the therapeutic areas of GI and inflammation/autoimmune



IBD is a High Value Indication

RECENT DEALS IN IBD/INFLAMMATION

	•				
DATE	COMPANY	PARTNER	COMPOUND	COMPLETED CLINICAL PHASE	TERMS
April 2014	Nogra Pharma	Celgene	Mongersen	Phase II	\$710 million upfront + \$1.9 billion milestones + royalty
July 2015	Receptos	Celgene	Ozanimod	Phase II	\$7.2 billion (aquisition)
Sept 2015	Galapagos	Gilead	Filgotinib	Phase II	\$300 million upfront + \$425 million equity investment + \$1.35 billion milestones + tiered royalty starting at 20%
June 2016	Pfizer	Shire	SHP647	Phase II	\$90 million upfront + \$460 million milestones + royalty
Oct 2016	MedImmune/ Astra Zeneca	Allergan	MEDI2070	Phase IIa	\$250 million upfront + \$1.27 billion milestones + royalty
Feb 2018	Theravance	Johnson & Johnson	TD-1473	Phase I	\$100 million upfront + \$900 million milestones + royalty

InDex Strengths

BLOCKBUSTER POTENTIAL

- Ulcerative Colitis (UC) is a debilitating disease with high unmet medical need
- Annual sales of biologics in UC amounts to >USD 5 billion
- Cobitolimod has high market potential as a safer and more efficacious alternative to biologics with a novel mechanism of action

LATE STAGE CLINICAL DEVELOPMENT

- Extensive clinical experience with excellent safety profile
- Main results from phase IIb dose optimisation study expected in Q4 2018
- Potential to provide substantially higher efficacy than current industry pipeline
- Attractive asset for potential partners
- Will validate broad portfolio of other DIMS assets with potential in inflammation

EXPERIENCED BOARD & MANAGEMENT

 Board and management with extensive experience from the pharmaceutical industry and listed companies

